(Q33909695)

29 July 2017

1 reference

https://doi.org/10.1002/14651858.CD001215.pub2

1 reference

29 December 2023

http://retractionwatch.com/2010/09/20/progressive-how-the-cochrane-library-handles-updates-in-progress/

title

Systemic treatments for metastatic cutaneous melanoma. (English)

1 reference

29 July 2017

T Crosby

1

1 reference

29 July 2017

R Fish

series ordinal

2

1 reference

29 July 2017

B Coles

series ordinal

3

1 reference

29 July 2017

M D Mason

series ordinal

4

1 reference

29 July 2017

1 January 2000

1 reference

Cochrane Database of Systematic Reviews

29 July 2017

1 reference

29 July 2017

CD001215

1 reference

29 July 2017

2

1 reference

Improved results with the addition of interferon alfa-2b to dacarbazine in the treatment of patients with metastatic malignant melanoma

29 July 2017

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001215

Crossref

reference URL

Randomized phase III trial of vinblastine, bleomycin, and cis-dichlorodiammine-platinum versus dacarbazine in malignant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001215

Crossref

reference URL

Comparison of the combination of 1, 3-bis(2-chloroethyl)-l-nitrosourea (BCNU) and vincristine with two dose schedules of 5-(3,3-dimethyl-l-triazino) imidazole 4-carboxamide (DTIC) in the treatment of disseminated malignant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001215

Crossref

reference URL

Controlled study of DTIC versus DTIC plus epirubicin in metastatic malignant melanoma

21 January 2018

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1002/14651858.CD001215

Treatment of metastatic malignant melanoma with dacarbazine plus tamoxifen

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1002/14651858.CD001215

Characteristics of prognosis and response to an imidazole carboxamide in malignant melanoma

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1002/14651858.CD001215

Clinical Evaluation of 5-(3,3-Dimethyl-1-Triazeno) Imidazole-4-Carboxamide in Malignant Melanoma and Other Neoplasms: Comparison of Twice-weekly and Daily Administration Schedules

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1002/14651858.CD001215

Multicenter randomized trial of dacarbazine alone or in combination with two different doses and schedules of interferon alfa-2a in the treatment of advanced melanoma

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1002/14651858.CD001215

Dacarbazine versus dacarbazine-vindesine in disseminated malignant melanoma: a randomized phase II study

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1002/14651858.CD001215

Combination phase 1-II study of imidazole carboxamide (NCS45388)

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1002/14651858.CD001215

Therapy of malignant melanoma with an imidazole carboxamide and bis-chloroethyl nitrosourea

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1002/14651858.CD001215

Imidazole carboxamide therapy in advanced malignant melanoma

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1002/14651858.CD001215

Chemotherapy of malignant melanoma

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1002/14651858.CD001215

Identifiers

DOI

10.1002/14651858.CD001215

1 reference

29 July 2017

1 reference